AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial

2011/03/17 by Peter A LeWitt, Peter A. LeWitt, Ali R Rezai +35 · 9 citations
Medicine · Neuroscience · #Nerve injury and regeneration #Neurological disorders and treatments #Parkinson's Disease Mechanisms and Treatments

paper · doi:10.1016/s1474-4422(11)70039-4

openalex publication_date 2011/03/17 · crossref created 2011/03/17 · crossref issued 2011/04/01 · crossref published 2011/04/01 · crossref published-print 2011/04/01 · openalex created_date 2025/10/10 · crossref deposited 2025/10/26 · crossref indexed 2026/07/02 · openalex updated_date 2026/07/29

Citations

• A Clinicopathologic Study of 100 Cases of Parkinson's Disease
• The Neuropsychiatric Inventory
• Studies of interference in serial verbal reactions.

Cited by

• Viral and nonviral delivery systems for gene delivery
• Retinal gene therapy in patients with choroideremia: initial findings from a phase 1/2 clinical trial
• Gene Therapy Approach with an Emphasis on Growth Factors: Theoretical and Clinical Outcomes in Neurodegenerative Diseases
• Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose escalation, open-label, phase 1/2 trial
• Mechanisms and therapeutic implications of the placebo effect in neurological and psychiatric conditions
• Gene therapy [wikipedia]
• Genetic engineering [wikipedia]
• Genetically modified organism [wikipedia]
• Management of Parkinson's disease [wikipedia]